Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7Q0Z

Crystal structure of CTX-M-14

Summary for 7Q0Z
Entry DOI10.2210/pdb7q0z/pdb
Related7Q0Y
DescriptorBeta-lactamase, GLYCEROL, SULFATE ION, ... (4 entities in total)
Functional Keywordslactamase, antibiotic, resistence, hydrolase
Biological sourceKlebsiella pneumoniae
Total number of polymer chains1
Total formula weight28644.97
Authors
Werner, N.,Perbandt, M.,Hinrichs, W.,Prester, A.,Rohde, H.,Aepfelbacher, M.,Betzel, C. (deposition date: 2021-10-17, release date: 2022-04-13, Last modification date: 2024-01-31)
Primary citationPerbandt, M.,Werner, N.,Prester, A.,Rohde, H.,Aepfelbacher, M.,Hinrichs, W.,Betzel, C.
Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as beta-lactamase inhibitors.
Sci Rep, 12:5510-5510, 2022
Cited by
PubMed Abstract: β-lactamases are a major cause of rapidly emerging and spreading antibiotic resistance. Currently β-lactamase inhibitors (BLIs) in clinical use act only on Ambler Class A, C and some class D lactamases. The urgent need to identify new BLIs recently lead to FDA approval of boron-based compounds BLIs, e.g. Vaborbactam. The boron-based proteasome inhibitors Bortezomib and Ixazomib are used in cancer therapy as multiple myeloma drugs but they also bind to Ser-/Thr- proteases. In this study we show the crystal structures of the β-lactamase CTX-M-14 with covalently bound Bortezomib and Ixazomib at high resolutions of 1.3 and 1.1 Å, respectively. Ixazomib is well defined in electron density whereas Bortezomib show some disorder which corresponds to weaker inhibition efficiency observed for Ixazomib. Both inhibitors mimic the deacylation transition state of β-lactam hydrolysis, because they replace the deacylating water molecule. We further investigate differences in binding of Bortezomib/Ixazomib to CTX-M-14 and its target proteases as well as known β-lactamase drugs. Our findings can help to use Bortezomib/Ixazomib as lead compounds for development of new BLIs.
PubMed: 35365689
DOI: 10.1038/s41598-022-09392-6
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1 Å)
Structure validation

227344

数据于2024-11-13公开中

PDB statisticsPDBj update infoContact PDBjnumon